Discovery and Development of HDAC Inhibitors: Approaches for the
Treatment of Cancer a Mini-review

Roshani      Patel; Arjun      Modi; Hitesh      Vekariya

doi:10.2174/0115701638286941240217102948

Abstract

Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics due to their ability to induce differentiation, cell cycle arrest, and apoptosis in cancer cells. In the present review, we have described the systemic discovery and development of HDAC inhibitors. Researchers across the globe have identified various small molecules like benzo[d][1,3]dioxol derivatives, belinostat analogs, pyrazine derivatives, quinazolin-4-one-based derivatives, 2,4-imidazolinedione derivatives, acridine hydroxamic acid derivatives, coumarin derivatives, tetrahydroisoquinoline derivatives, thiazole-5-carboxamide, salicylamide derivatives, β-peptoid-capped HDAC inhibitors, quinazoline derivatives, benzimidazole and benzothiazole derivatives, and β- elemene scaffold containing HDAC inhibitors. Most of the scaffolds have shown attractive IC50 (μM) in various cell lines like HDAC1, HDAC2, HDAC6, PI3K, HeLa, MDA-MB-231, MCF-10A, MCF-7, U937, K562 and Bcr-Abl cell lines.

Graphical Abstract

[1]
Kouzarides T. Chromatin modifications and their function. Cell  2007; 128(4): 693-705.
 [http://dx.doi.org/10.1016/j.cell.2007.02.005] [PMID: 17320507]

[2]
Marks PA, Xu WS, Pascual-Leone A. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med  2019; 25(1): 600-8.

[3]
Pao PC, Tsai LH. Histone deacetylases 1 and 2 in memory function. ACS Chem Neurosci  2022; 13(7): 848-58.
 [http://dx.doi.org/10.1021/acschemneuro.1c00775] [PMID: 35263084]

[4]
Seto E, Yoshida M. Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb Perspect Biol  2014; 6(4): a018713.
 [http://dx.doi.org/10.1101/cshperspect.a018713] [PMID: 24691964]

[5]
Ho TCS, Chan AHY, Ganesan A. Thirty years of HDAC inhibitors: 2020 hindsight. J Med Chem  2020; 63(21): 12460-84.
 [http://dx.doi.org/10.1021/acs.jmedchem.0c00830] [PMID: 32608981]

[6]
Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov  2014; 13(9): 673-91.
 [http://dx.doi.org/10.1038/nrd4360] [PMID: 25131830]

[7]
Fedele P, Orlando L, Cinieri S. Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin Investig Drugs  2017; 26(11): 1199-206.
 [http://dx.doi.org/10.1080/13543784.2017.1386172] [PMID: 28952409]

[8]
Cao LL, Song X, Pei L, Liu L, Wang H, Jia M. Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer. Medicine  2017; 96(31): e7663.
 [http://dx.doi.org/10.1097/MD.0000000000007663] [PMID: 28767587]

[9]
Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci  2009; 32(11): 591-601.
 [http://dx.doi.org/10.1016/j.tins.2009.06.002] [PMID: 19775759]

[10]
Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog  2014; 10(4): e1004071.
 [http://dx.doi.org/10.1371/journal.ppat.1004071] [PMID: 24722454]

[11]
Chun P. Therapeutic effects of histone deacetylase inhibitors on kidney disease. Arch Pharm Res  2018; 41(2): 162-83.
 [http://dx.doi.org/10.1007/s12272-017-0998-7] [PMID: 29230688]

[12]
Das Gupta K, Shakespear MR, Iyer A, Fairlie DP, Sweet MJ. Histone deacetylases in monocyte/macrophage development, activation and metabolism: Refining HDAC targets for inflammatory and infectious diseases. Clin Transl Immunology  2016; 5(1): e62.
 [http://dx.doi.org/10.1038/cti.2015.46] [PMID: 26900475]

[13]
Yoon S, Eom GH. HDAC and HDAC inhibitor: From cancer to cardiovascular diseases. Chonnam Med J  2016; 52(1): 1-11.
 [http://dx.doi.org/10.4068/cmj.2016.52.1.1] [PMID: 26865995]

[14]
Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol  2007; 25(1): 84-90.
 [http://dx.doi.org/10.1038/nbt1272] [PMID: 17211407]

[15]
Mann BS, Bolen CR. HDAC inhibitors for the treatment of cancer. J Cell Physiol  2019; 234(6): 8491-505.

[16]
Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J  2001; 20(24): 6969-78.
 [http://dx.doi.org/10.1093/emboj/20.24.6969] [PMID: 11742974]

[17]
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov  2006; 5(9): 769-84.
 [http://dx.doi.org/10.1038/nrd2133] [PMID: 16955068]

[18]
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer  2006; 6(1): 38-51.
 [http://dx.doi.org/10.1038/nrc1779] [PMID: 16397526]

[19]
Patnaik A, Rowinsky EK, Villalona MA, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res  2002; 8(7): 2142-8.
 [PMID: 12114414]

[20]
Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood  2007; 109(7): 2781-90.
 [http://dx.doi.org/10.1182/blood-2006-05-021873] [PMID: 17179232]

[21]
Fan W, Zhang L, Wang X, Jia H, Zhang L. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps. J Enzyme Inhib Med Chem  2021; 36(1): 707-18.
 [http://dx.doi.org/10.1080/14756366.2021.1892089] [PMID: 33663315]

[22]
Zhang JH, Mottamal M, Jin HS, et al. Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors. Future Med Chem  2019; 11(21): 2765-78.
 [http://dx.doi.org/10.4155/fmc-2018-0587] [PMID: 31702394]

[23]
Al-Sanea MM, Gotina L, Mohamed MF, et al. Design, synthesis and biological evaluation of new HDAC1 and HDAC2 inhibitors endowed with ligustrazine as a novel cap moiety. Drug Des Devel Ther  2020; 14: 497-508.
 [http://dx.doi.org/10.2147/DDDT.S237957] [PMID: 32103894]

[24]
Thakur A, Tawa GJ, Henderson MJ, et al. Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K/HDAC inhibitors. J Med Chem  2020; 63(8): 4256-92.
 [http://dx.doi.org/10.1021/acs.jmedchem.0c00193] [PMID: 32212730]

[25]
Liang T, Hou X, Zhou Y, Yang X, Fang H. Design, synthesis, and biological evaluation of 2,4-imidazolinedione derivatives as HDAC6 isoform-selective inhibitors. ACS Med Chem Lett  2019; 10(8): 1122-7.
 [http://dx.doi.org/10.1021/acsmedchemlett.9b00084] [PMID: 31413795]

[26]
Chen J, Li D, Li W, et al. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Bioorg Med Chem  2018; 26(14): 3958-66.
 [http://dx.doi.org/10.1016/j.bmc.2018.06.016] [PMID: 29954683]

[27]
Yang F, Zhao N, Song J, et al. Design, synthesis and biological evaluation of novel coumarin-based hydroxamate derivatives as histone deacetylase (HDAC) inhibitors with antitumor activities. Molecules  2019; 24(14): 2569.
 [http://dx.doi.org/10.3390/molecules24142569] [PMID: 31311163]

[28]
Taha TY, Aboukhatwa SM, Knopp RC, et al. Design, synthesis, and biological evaluation of tetrahydroisoquinoline-based histone deacetylase 8 selective inhibitors. ACS Med Chem Lett  2017; 8(8): 824-9.
 [http://dx.doi.org/10.1021/acsmedchemlett.7b00126] [PMID: 28835796]

[29]
Chen X, Zhao S, Wu Y, Chen Y, Lu T, Zhu Y. Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors. RSC Advances  2016; 6(105): 103178-84.
 [http://dx.doi.org/10.1039/C6RA21271A]

[30]
Kim JH, Ali KH, Oh YJ, Seo YH. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group. Medicine  2022; 101(17): e29049.
 [http://dx.doi.org/10.1097/MD.0000000000029049] [PMID: 35512065]

[31]
Reßing N, Marquardt V, Gertzen CGW, et al. Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. MedChemComm  2019; 10(7): 1109-15.
 [http://dx.doi.org/10.1039/C8MD00454D] [PMID: 31391882]

[32]
Yao D, Li C, Jiang J, et al. Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer. Eur J Med Chem  2020; 205(112648): 112648.
 [http://dx.doi.org/10.1016/j.ejmech.2020.112648] [PMID: 32791401]

[33]
He J, Wang S, Liu X, et al. Synthesis and biological evaluation of HDAC inhibitors with a novel zinc binding group. Front Chem  2020; 8(256): 256.
 [http://dx.doi.org/10.3389/fchem.2020.00256] [PMID: 32351936]

[34]
Myeong AC, SunYou P, HyeYun C, Yoojin S. Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes. Sci Rep  2019; 9(13187): 1-12.

[35]
Yuan G, Jilong D, Xiawen D, et al. Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β-elemene scaffold. J Enzyme Inhib Med Chem  2023; 38(1): 1-22.
 [PMID: 36305251]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115701638286941240217102948	Print ISSN 1570-1638
Publisher Name Bentham Science Publisher	Online ISSN 1875-6220

Current Drug Discovery Technologies

Discovery and Development of HDAC Inhibitors: Approaches for the Treatment of Cancer a Mini-review

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract